OA
WeChat
Home
About Us
Investor Relations
R & D
Careers
Contact Us
Investor Relations
Corporate Information
Business Overview
Board of Directors,Senior Management and Academic Advisers
Corporate Governance
Financial Information
Shareholdings of Directors and CEO
Financial Reports
Stock Information
Corporate Communications
Announcements & Circulars
Returns on Share Capital
Multimedia
Corporate Presentation
Video
Corporate Pictures
Contact Us
Location：
>
Home
>
Inverstor Relations
>
Corporate Communications
>
Announcements & Circulars
You will need the Adobe Acrobat Reader 7.0 and Asian Font Packs to view the PDF.
If you do not have any of the above, please download
"Acrobat Reader"
and
"Asian Font Packs for Acrobat Reader 7.0"
.
Please select year
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2022-04-19
PROPOSED AMENDMENTS TO ARTICLES OF ASSOCIATION
2022-03-27
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2021 AND CLOSURE OF REIGSTER OF MEMBERS
2022-03-27
ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
2022-03-14
DATE OF BOARD MEETING
2022-02-16
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
2022-02-16
ANNOUNCEMENT (1) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER AND (2) APPOINTMENT OF CHIEF EXECUTIVE OFFICER
2022-01-26
(1) DISCLOSEABLE TRANSACTION-DISPOSAL OF EQUITY INTERESTS IN THE TARGET COMPANY; (2) UPDATE ON GAIN ON PREVIOUS DISPOSAL
2021-12-22
UPDATE ON JOINT VENTURE COMPANY-EARLY COMPLETION OF PATIENT ENROLLMENT OF EBRONUCIMAB (PCSK9 MONOCLONAL ANTIBODY, AK102) IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERL
2021-09-23
BUSINESS UPDATE-PRODUCT COOPERATION AGREEMENTS
2021-09-09
BUSINESS UPDATE- INITIATION OF PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA OF AK102 AND INCREASE IN CAPITAL CONTRIBUTION IN JOINT VENTURE
Total
30
pages
Current
6
/
30
First
Prev
Next
Last
GO